Logo image of SERA

SERA PROGNOSTICS INC-A (SERA) Stock Price, Quote, News and Overview

NASDAQ:SERA - Nasdaq - US81749D1072 - Common Stock - Currency: USD

3.475  +0.08 (+2.51%)

SERA Quote, Performance and Key Statistics

SERA PROGNOSTICS INC-A

NASDAQ:SERA (4/22/2025, 3:58:55 PM)

3.475

+0.08 (+2.51%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High12.36
52 Week Low2.99
Market Cap130.87M
Shares37.66M
Float31.63M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07/amc
IPO07-15 2021-07-15


SERA short term performance overview.The bars show the price performance of SERA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40 -50

SERA long term performance overview.The bars show the price performance of SERA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 -60

The current stock price of SERA is 3.475 USD. In the past month the price decreased by -10.55%. In the past year, price decreased by -68.47%.

SERA PROGNOSTICS INC-A / SERA Daily stock chart

SERA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.17 307.29B
AMGN AMGEN INC 14.05 149.69B
GILD GILEAD SCIENCES INC 22.89 131.53B
VRTX VERTEX PHARMACEUTICALS INC 1691.57 126.11B
REGN REGENERON PHARMACEUTICALS 12.83 64.02B
ARGX ARGENX SE - ADR 322.75 36.66B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.76B
ONC BEIGENE LTD-ADR N/A 27.27B
BNTX BIONTECH SE-ADR N/A 25.20B
SMMT SUMMIT THERAPEUTICS INC N/A 20.17B
NTRA NATERA INC N/A 19.56B
BIIB BIOGEN INC 7.22 17.40B

About SERA

Company Profile

SERA logo image Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 57 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.

Company Info

SERA PROGNOSTICS INC-A

2749 E. Parleys Way, Suite 200

Salt Lake City UTAH US

CEO: Gregory C. Critchfield

Employees: 56

Company Website: https://www.seraprognostics.com/

Investor Relations: https://seraprognostics.com/investors/

Phone: 18015050278

SERA PROGNOSTICS INC-A / SERA FAQ

What is the stock price of SERA PROGNOSTICS INC-A today?

The current stock price of SERA is 3.475 USD. The price increased by 2.51% in the last trading session.


What is the ticker symbol for SERA PROGNOSTICS INC-A stock?

The exchange symbol of SERA PROGNOSTICS INC-A is SERA and it is listed on the Nasdaq exchange.


On which exchange is SERA stock listed?

SERA stock is listed on the Nasdaq exchange.


What is SERA PROGNOSTICS INC-A worth?

SERA PROGNOSTICS INC-A (SERA) has a market capitalization of 130.87M USD. This makes SERA a Micro Cap stock.


How many employees does SERA PROGNOSTICS INC-A have?

SERA PROGNOSTICS INC-A (SERA) currently has 56 employees.


What are the support and resistance levels for SERA PROGNOSTICS INC-A (SERA) stock?

SERA PROGNOSTICS INC-A (SERA) has a support level at 3.25 and a resistance level at 3.47. Check the full technical report for a detailed analysis of SERA support and resistance levels.


Is SERA PROGNOSTICS INC-A (SERA) expected to grow?

The Revenue of SERA PROGNOSTICS INC-A (SERA) is expected to grow by 763.64% in the next year. Check the estimates tab for more information on the SERA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SERA PROGNOSTICS INC-A (SERA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SERA PROGNOSTICS INC-A (SERA) stock pay dividends?

SERA does not pay a dividend.


When does SERA PROGNOSTICS INC-A (SERA) report earnings?

SERA PROGNOSTICS INC-A (SERA) will report earnings on 2025-05-07, after the market close.


What is the Price/Earnings (PE) ratio of SERA PROGNOSTICS INC-A (SERA)?

SERA PROGNOSTICS INC-A (SERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).


What is the Short Interest ratio of SERA PROGNOSTICS INC-A (SERA) stock?

The outstanding short interest for SERA PROGNOSTICS INC-A (SERA) is 2.94% of its float. Check the ownership tab for more information on the SERA short interest.


SERA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SERA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SERA. SERA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SERA Financial Highlights

Over the last trailing twelve months SERA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 14.66% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -45.33%
ROE -68.82%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%-41.46%
EPS 1Y (TTM)14.66%
Revenue 1Y (TTM)-74.42%

SERA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to SERA. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of -0.97% and a revenue growth 763.64% for SERA


Ownership
Inst Owners68.81%
Ins Owners4.62%
Short Float %2.94%
Short Ratio6.42
Analysts
Analysts85
Price TargetN/A
EPS Next Y-0.97%
Revenue Next Year763.64%